49 Wealth Management’s Cogent Biosciences COGT Stock Holding History

49 Wealth Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$239K	Sell	6,221 -210	-3%	-$7.75K	0.02%	170
2025 Q4	$228K	Sell	6,431 -3,612	-36%	-$102K	0.02%	177
2025 Q3	$144K	Sell	10,043 -5,465	-35%	-$64.7K	0.01%	187
2025 Q2	$111K	Buy	15,508 +2,476	+19%	+$13.7K	0.01%	173
2025 Q1	$78.1K	Buy	13,032 +450	+4%	+$3.53K	0.01%	179
2024 Q4	$98.1K	Hold	12,582	–	–	0.01%	164
2024 Q3	$136K	Hold	12,582	–	–	0.02%	168
2024 Q2	$112K	Sell	12,582 -555	-4%	-$4.21K	0.02%	147
2024 Q1	$90.6K	Buy	13,137 +2,236	+21%	+$13.8K	0.02%	121
2023 Q4	$64.1K	Buy	+10,901	New	+$83.5K	0.02%	119

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

49 Wealth Management's COGT Position: Q1 2026 in Review

49 Wealth Management reduced its Cogent Biosciences (COGT) stake by 3.3% in Q1 2026, selling an estimated $7.75K and leaving 6,221 shares worth $239K. The position accounts for 0.02% of the portfolio, ranked #170.

49 Wealth Management first reported a position in COGT in Q4 2023 and has held it in 10 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

49 Wealth Management held 6,221 shares of Cogent Biosciences worth $239K as of Q1 2026.
49 Wealth Management sold 210 Cogent Biosciences shares in Q1 2026, an estimated $7.75K.
Cogent Biosciences made up 0.02% of 49 Wealth Management's portfolio in Q1 2026, its #170 holding.
49 Wealth Management first reported a position in Cogent Biosciences in Q4 2023 and has held it in 10 quarters since.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on 49 Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.